These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 21955614)
1. Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Manavalan TT; Teng Y; Appana SN; Datta S; Kalbfleisch TS; Li Y; Klinge CM Cancer Lett; 2011 Dec; 313(1):26-43. PubMed ID: 21955614 [TBL] [Abstract][Full Text] [Related]
2. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Cittelly DM; Das PM; Spoelstra NS; Edgerton SM; Richer JK; Thor AD; Jones FE Mol Cancer; 2010 Dec; 9():317. PubMed ID: 21172025 [TBL] [Abstract][Full Text] [Related]
4. Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Muluhngwi P; Krishna A; Vittitow SL; Napier JT; Richardson KM; Ellis M; Mott JL; Klinge CM Cancer Lett; 2017 Mar; 388():230-238. PubMed ID: 27986463 [TBL] [Abstract][Full Text] [Related]
5. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Zhong S; Li W; Chen Z; Xu J; Zhao J Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. Miller TE; Ghoshal K; Ramaswamy B; Roy S; Datta J; Shapiro CL; Jacob S; Majumder S J Biol Chem; 2008 Oct; 283(44):29897-903. PubMed ID: 18708351 [TBL] [Abstract][Full Text] [Related]
7. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. Kong X; Ding X; Li X; Gao S; Yang Q Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542 [TBL] [Abstract][Full Text] [Related]
8. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor. Coser KR; Wittner BS; Rosenthal NF; Collins SC; Melas A; Smith SL; Mahoney CJ; Shioda K; Isselbacher KJ; Ramaswamy S; Shioda T Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14536-41. PubMed ID: 19706540 [TBL] [Abstract][Full Text] [Related]
9. δEF1 down-regulates ER-α expression and confers tamoxifen resistance in breast cancer. Guo S; Li Y; Tong Q; Gu F; Zhu T; Fu L; Yang S PLoS One; 2012; 7(12):e52380. PubMed ID: 23285017 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049 [TBL] [Abstract][Full Text] [Related]
11. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1. Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687 [TBL] [Abstract][Full Text] [Related]
12. Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. Fan P; Cunliffe HE; Griffith OL; Agboke FA; Ramos P; Gray JW; Jordan VC Eur J Cancer; 2014 Nov; 50(16):2877-86. PubMed ID: 25212499 [TBL] [Abstract][Full Text] [Related]
13. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721 [TBL] [Abstract][Full Text] [Related]
14. Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cells. Semlali A; Oliva J; Badia E; Pons M; Duchesne MJ J Steroid Biochem Mol Biol; 2004 Mar; 88(3):247-59. PubMed ID: 15120418 [TBL] [Abstract][Full Text] [Related]
15. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Wei Y; Lai X; Yu S; Chen S; Ma Y; Zhang Y; Li H; Zhu X; Yao L; Zhang J Breast Cancer Res Treat; 2014 Sep; 147(2):423-31. PubMed ID: 25007959 [TBL] [Abstract][Full Text] [Related]
16. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276 [TBL] [Abstract][Full Text] [Related]
17. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Li J; Lu M; Jin J; Lu X; Xu T; Jin S Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449 [TBL] [Abstract][Full Text] [Related]
18. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Howe EN; Cochrane DR; Richer JK Breast Cancer Res; 2011 Apr; 13(2):R45. PubMed ID: 21501518 [TBL] [Abstract][Full Text] [Related]
19. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135 [TBL] [Abstract][Full Text] [Related]
20. miRNA expression patterns in chemoresistant breast cancer tissues. Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]